Biotech News

PDS Biotech Reports Third Quarter 2026 Financial Results

PDS Biotechnology Corporation (PDSB)PDS Biotechnology CorporationEarnings

PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a clinical-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today provided a business and clinical programs update and reported financial results for the quarter ended September 30, 2026.

Related news

PDS Biotechnology Corporation

Targeted Cancer Immunotherapy PDS Biotechnology develops immunotherapies intended to activate antitumor immunity while directing immune stimulation toward the tumor microenvironment. PDS0301 PDS0301 is a tumor-targeted interleukin-12 immunocytokine designed to enhance local immune activity while limiting systemic IL-12 exposure. It is...

Recent company news

Stock data

Close
0.81 USD
Market cap
64.75M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States